Literature DB >> 1736561

Oxidative status of lipoproteins in coronary disease patients.

K Z Liu1, T E Cuddy, G N Pierce.   

Abstract

Oxidized low-density lipoprotein (LDL) may play an important role in atherogenesis. The oxidative status of isolated LDL and very low-density lipoprotein (VLDL) were investigated in 23 patients with proven coronary disease and in 23 healthy asymptomatic control subjects. Oxidized cholesterol (4-cholesten-3-one and 20 alpha-OH cholesterol) was identified in LDL and VLDL from both groups. The content of cholesterol and 4-cholesten-3-one in LDL from patients was significantly increased in comparison with values from the control subjects. Lipid peroxidation, as assessed by malondialdehyde (MDA) formation, was barely detectable in native LDL and VLDL from the two groups. However, after incubation with a free radical-producing system, MDA levels in LDL from patients were significantly higher than those in control subjects. Lysine reactivity in LDL after incubation with an oxidizing agent, CuSO4, was similar between groups. However, lysine reactivity to CuSO4 in VLDL from patients was less than that in control subjects. Our results suggest that LDL levels from patients with coronary disease have an elevated oxidized cholesterol content and are more susceptible to peroxidative modification. Conversely, the LDL apoprotein does not appear to have been oxidatively modified in these patients. The data are consistent with a role for oxidized LDL in coronary artery disease and indicate that the LDL lipid may be an important oxidation site.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1736561     DOI: 10.1016/0002-8703(92)90636-a

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  9 in total

1.  [Vitamin E distribution of lipoproteins in patients with coronary heart disease].

Authors:  T Purcz; W Reuter; B Vorberg; I Sauer; A Neugebauer
Journal:  Z Ernahrungswiss       Date:  1996-09

2.  Cholesterol-rich low density lipoproteins are also more oxidized.

Authors:  Vadim Lankin; Margus Viigimaa; Alla Tikhaze; Elena Kumskova; Galina Konovalova; Jelena Abina; Galina Zemtsovskaya; Tatyana Kotkina; Elena Yanushevskaya; Tatyana Vlasik
Journal:  Mol Cell Biochem       Date:  2011-06-07       Impact factor: 3.396

3.  Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro.

Authors:  R Menéndez; R Más; A M Amor; R M González; J C Fernández; I Rodeiro; M Zayas; S Jiménez
Journal:  Br J Clin Pharmacol       Date:  2000-09       Impact factor: 4.335

4.  Alzheimer disease beta-amyloid activity mimics cholesterol oxidase.

Authors:  Luigi Puglielli; Avi L Friedlich; Kenneth D R Setchell; Seiichi Nagano; Carlos Opazo; Robert A Cherny; Kevin J Barnham; John D Wade; Simon Melov; Dora M Kovacs; Ashley I Bush
Journal:  J Clin Invest       Date:  2005-08-25       Impact factor: 14.808

5.  Low-fat, monounsaturate-rich diets reduce susceptibility of low density lipoproteins to peroxidation ex vivo.

Authors:  D J O'Bryne; S F O'Keefe; R B Shireman
Journal:  Lipids       Date:  1998-02       Impact factor: 1.880

6.  Effects of ACE inhibitors on oxidation of human low density lipoprotein.

Authors:  E G Godfrey; J Stewart; H J Dargie; J L Reid; M Dominiczak; C A Hamilton; J McMurray
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

7.  Kinetic analysis of LDL oxidation in IHD and IHD risk subjects in Indian population.

Authors:  Yashika Gupta; V Mallika; D K Srivastava
Journal:  Indian J Clin Biochem       Date:  2003-01

8.  Muscle ubiquinone in male effort angina patients.

Authors:  J Karlsson; L Lin; S Gunnes; C Sylvén; H Aström
Journal:  Mol Cell Biochem       Date:  1996-03-23       Impact factor: 3.396

9.  The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation.

Authors:  M I Mackness; C Abbott; S Arrol; P N Durrington
Journal:  Biochem J       Date:  1993-09-15       Impact factor: 3.857

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.